IL22 and type 2 diabetes mellitus: In Mtb-infected T2DM mice, recombinant IL-22 treatment or adoptive transfer of ILC3s significantly reduced bacterial burden, reduced inflammation, improved lipid metabolism and prolonged survival in mice.